Non-Small Cell Lung Cancer Treatment Market size was over USD 18.91 billion in 2023 and is likely to reach USD 88.45 billion by the end of 2036, witnessing around 12.6% CAGR during the forecast period i.e., between 2024-2036. In the year 2024, the industry size of non-small cell lung cancer treatment is assessed at USD 20.82 billion.
The rising prevalence of non-small cell lung cancer, along with the growing awareness about the disease are expected to fuel the progress of this market. The growth of the non-small cell lung cancer treatment market can also be attributed to factors such as the increase in share of smoking population and the greater exposure to toxins on a global level. According to the data collected from World Health Organization, in 2020, the estimated new cases and number of deaths from lung cancer globally, were 2.21 million and 1.80 million, respectively.
Growth Drivers
Challenges
|
Base Year |
2023 |
|
Forecast Year |
2024-2036 |
|
CAGR |
12.6% |
|
Base Year Market Size (2023) |
USD 18.91 billion |
|
Forecast Year Market Size (2036) |
USD 88.45 billion |
|
Regional Scope |
|
The non-small cell lung cancer treatment market is segmented on the basis of treatment type into surgery, radiofrequency ablation, radiation therapy, chemotherapy, targeted therapy, immunotherapy, and others, out of which, the targeted therapy segment is anticipated to grab the largest share by the end of 2021 on account of higher adoption rates and better efficiency of targeted therapy than chemotherapy. Moreover, targeted therapy is widely being used as an adjuvant treatment alongside chemotherapy, which is also projected to contribute to the growth of the segment during the forecast period.
On the basis of end-user, the general medical & surgical hospitals’ segment in the global non-small cell lung cancer treatment market is projected to grow with a significant CAGR over the forecast period. The growth of the segment can be attributed to the fact that general medical & surgical hospitals have well-developed healthcare infrastructure due to their better financial capabilities, which leads to greater proportion of population affected with non-small cell lung cancer choosing this segment for treatment.
Our in-depth analysis of the global market includes the following segments:
|
By Treatment Type |
|
|
By End-User |
|
Geographically, the non-small cell lung cancer treatment market is segmented into North America, Latin America, Europe, Asia Pacific and the Middle East & Africa region. The market in the Asia Pacific industry is anticipated to hold largest revenue share by 2036, owing to increasing diagnosis rates of non-small cell lung cancer, and need to develop innovative treatment solutions in the region.
Furthermore, in 2021, the market in North America is evaluated to occupy the largest share in terms of revenue, owing to the growing investment of governmental and non-governmental agencies in lung cancer research, accompanied by the presence of leading healthcare service providers in the region. Along with this, North America also leads in terms of adoption of advanced immunotherapies along with other therapies, which is also expected to contribute to the market growth in the region. Alternatively, the market in Europe is also anticipated to occupy a significant share in the non-small cell lung cancer treatment market on account of its proven success in terms of research & development and a high prevalence of non-small lung cancer in the region. In Europe, lung cancer is the leading cause of cancer-related deaths and about 85% of all lung cancer cases are classified as those of non-small cell lung cancer.
Author Credits: Radhika Pawar
Copyright © 2024 Research Nester. All Rights Reserved
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Have questions before ordering this report?